Search Results - paul carlier

7 Results

Sort By:

Highly Species-Selective Insecticidal Carbamates for Mosquito Control

ABOUT THE TECHNOLOGYWith about 198 million cases and 584,000 deaths just in 2013, malaria has been and continues to be a prominent health concern all over the world. In some areas, the method of defense against the vector, Anopheles gambiae, is profoundly limited. For example, many of those in sub-Saharan Africa rely on insecticide-treated nets (I...

Published: 6/1/2015 | Inventor(s): Joshua Hartsel, Ming Ma, Troy Anderson, Ranginee Choudhury, Paul Carlier, Jeffrey Bloomquist, Sally Paulson, Eric Wong

Keywords(s): Agriculture/Pest Control

Category(s): Chemicals, Biomedical

Structurally Novel Insecticides for the Malaria Mosquito

Structurally Novel Insecticides for the Malaria Mosquito:ABOUT THE TECHNOLOGYWith about 198 million cases and 584,000 deaths just in 2013, malaria has been and continues to be a prominent health concern all over the world. Only one class of approved insecticides, pyrethroids, is routinely used on insecticide-treated nets (ITNs), which have the pote...

Published: 6/1/2015 | Inventor(s): Paul Carlier, Eugene Camerino, Dawn Wong, Jeffrey Bloomquist

Keywords(s): Agriculture/Pest Control

Category(s): Medical, Chemicals

Novel Methylerythritol Phosphate Pathway Inhibitors

The apicoplast is essential to the malaria parasite and its main function during asexual blood stages is to provide the isoprenoid precursor isopentenyl diphosphate (MEP) pathway. Without IPP, the parasite cannot synthesize isoprenoids; this IPP deficit is cytocidal and may also reduce the ability of the parasite to invade host cells. Since human...

Published: 10/29/2014 | Inventor(s): Paul Carlier, Maria Belen Cassera, Emilio Merino, Zhong-Ke Yao

Keywords(s):

Category(s): Medical, Agriculture, Animal/Veterinary, Biomedical, Therapeutic

New Antidepressant Compounds (3)

Currently available antidepressant drugs treat only 70% of persons diagnosed with depressive illness. These drugs show a profile of blocking reuptake of serotonin and norepinephrine. Several lines of evidence, including the NIH STAR*D study suggest that addition of a dopamine reuptake-blocking action could treat refractory depressed individuals. ...

Published: 4/11/2014 | Inventor(s): Paul Carlier, Christopher Monceaux, Tom Simpson, Mike Wood, Mark Chapdelaine, Dan Hill, Jim Kang, Jim Woods, Elliott Richelson, Abdul Fauq, Dola Sinha

Keywords(s):

Category(s): Drug Discovery

New Antidepressant Compounds (2)

Published: 4/11/2014 | Inventor(s): Paul Carlier, Christopher Monceaux, Tom Simpson, Mike Wood, Mark Chapdelaine, Dan Hill, Jim Kang, Jim Woods, Elliott Richelson, Abdul Fauq, Dola Sinha

Keywords(s):

Category(s): Drug Discovery

New Antidepressant Compounds (1)

Published: 4/11/2014 | Inventor(s): Paul Carlier, Christopher Monceaux, Tom Simpson, Mike Wood, Mark Chapdelaine, Dan Hill, Jim Kang, Jim Woods, Elliott Richelson, Abdul Fauq, Dola Sinha

Keywords(s): Medical/Therapeutic

Category(s): Drug Discovery

Novel Small-Molecule Antidepressants

These potential antidepressant compounds have a novel mechanism of action – blockade of transporters for the neurotransmitters norepinephrine, serotonin, and dopamine. This novel “triple reuptake blockade” approach holds promise for a more effective and rapidly-acting antidepressant.

Published: 4/1/2014 | Inventor(s): Paul Carlier, Elliott Richelson

Keywords(s): Pharmaceuticals & Biotechnology

Category(s): Medical, Biotechnology